Uses
17-Phenyl trinor prostaglandin E2 ethyl amide (17-Phenyl trinor PGE2 ethyl amide) is a EP1 receptor agonist. 17-Phenyl trinor prostaglandin E2 ethyl amide aggravates renal dysfunction and glomerulosclerosis[1].
in vivo
17-Phenyl trinor prostaglandin E2 ethyl amide (0.3 μg/g; i.p.; three times a week for 12 weeks) aggravates renal dysfunction and glomerulosclerosis in fivesixths nephrectomy renal fibrosis model mice[1].
| Animal Model: | 8-12 weeks, 15-20 g, C57/BL6 male mice (fivesixths nephrectomy renal fibrosis model)[1] |
| Dosage: | 0.3 μg/g |
| Administration: | I.p.; three times a week for 12 weeks |
| Result: | Increased the plasma blood urea nitrogen (BUN) levels and plasma creatinine (Cr) concentration, increased the extracellular matrix and the area of collagen deposition, upregulated the protein of expression of Col1, GRP78, TRPC1 and PERK in 5/6 Nx mice. |
References
[1] Chen X, et al. Effect of selective inhibition or activation of PGE2 EP1 receptor on glomerulosclerosis. Mol Med Rep. 2020 Oct;22(4):2887-2895. DOI:
10.3892/mmr.2020.11353